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Background: Coronavirus disease 2019 (COVID-19) patients are at high risk
of neurological complications consequent to several factors including persistent
hypotension. There is a paucity of data on the effects of therapeutic interventions
designed to optimize systemic hemodynamics on cerebral autoregulation (CA) in this
group of patients.
Methods: Single-center, observational prospective study conducted at San Martino
Policlinico Hospital, Genoa, Italy, from October 1 to December 15, 2020. Mechanically
ventilated COVID-19 patients, who had at least one episode of hypotension and received
a passive leg raising (PLR) test, were included. They were then treated with fluid challenge
(FC) and/or norepinephrine (NE), according to patients’ clinical conditions, at different
moments. The primary outcome was to assess the early effects of PLR test and of FC
and NE [when clinically indicated to maintain adequate mean arterial pressure (MAP)]
on CA (CA index) measured by transcranial Doppler (TCD). Secondary outcomes were
to evaluate the effects of PLR test, FC, and NE on systemic hemodynamic variables,
cerebral oxygenation (rSo2), and non-invasive intracranial pressure (nICP).
Results: Twenty-three patients were included and underwent PLR test. Of these,
22 patients received FC and 14 were treated with NE. The median age was 62
years (interquartile range = 57–68.5 years), and 78% were male. PLR test led to a
low CA index [58% (44–76.3%)]. FC and NE administration resulted in a CA index
of 90.8% (74.2–100%) and 100% (100–100%), respectively. After PLR test, nICP
based on pulsatility index and nICP based on flow velocity diastolic formula was
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increased [18.6 (17.7–19.6) vs. 19.3 (18.2–19.8) mm Hg, p = 0.009, and 12.9 (8.5–18)
vs. 15 (10.5–19.7) mm Hg, p = 0.001, respectively]. PLR test, FC, and NE resulted in a
significant increase in MAP and rSo2.
Conclusions: In mechanically ventilated severe COVID-19 patients, PLR test adversely
affects CA. An individualized strategy aimed at assessing both the hemodynamic and
cerebral needs is warranted in patients at high risk of neurological complications.
Keywords: fluid challenge, norepinephrine, passive leg raising test, cerebral oxygenation, cerebral autoregulation
INTRODUCTION
Severe hypoxemic respiratory failure is the main reason for
intensive care unit (ICU) admission in coronavirus disease 2019
(COVID-19) patients (1–3).
However, COVID-19 is a multisystemic disease (4),
with significant implications for the brain (5–7). Different
mechanisms related to neurological damage have been proposed,
such as a direct viral neurotropism, hypercoagulable state, and
systemic complications including hypoxia and hypotension (8).
Therefore, it seems logical that in order to protect the brain, with
optimized cerebral perfusion and oxygenation, hemodynamic
stability should be maintained (6).
The current target ofmean arterial pressure (MAP) commonly
used in the general ICU population (>65mm Hg) (7) may
not always be sufficient to ensure adequate cerebral perfusion,
as the brain might potentially require higher values of MAP
to optimize cerebral perfusion pressure (CPP) and maintain
cerebral autoregulation (CA) (9, 10), especially in the COVID-
19 patients who often present altered cerebrovascular dynamics
(5). A commonly used functional hemodynamic test to assess
fluid responsiveness is the passive leg raising (PLR) test, which
causes a shift of intravascular fluids from the legs to the
abdominal compartment. Methods proposed to optimize MAP
have different pathophysiological mechanisms and include a
quick infusion of a small amount of fluids [the so-called
fluid challenge (FC)], which provides an extrinsic increase in
intravascular volume, and vasopressors, such as norepinephrine
(NE), generally used in fluids non-responders, which increase
vascular tone.
As no data are available regarding the effect of PLR
test on cerebral function and in particular autoregulation
in mechanically ventilated severe COVID-19 patients, we
conducted a prospective observational study; the primary
outcome was to assess the early effect of PLR test and of
Abbreviations: ABP, arterial blood pressure; CA, cerebral autoregulation;
COVID-19, coronavirus disease 2019; CPP, cerebral perfusion pressure; ETCO2,
end-tidal carbon dioxide; FC, fluid challenge; FIO2, fraction of inspired oxygen;
FVd, diastolic flow velocity; FVm, mean flow velocity; FVs, systolic flow velocity;
Hb, hemoglobin; ICU, intensive care unit; MAP, mean arterial pressure; MCAs,
middle cerebral arteries; nCPP, non-invasive cerebral perfusion pressure; NE,
norepinephrine; nICP, non-invasive intracranial pressure; NIRS, near-infrared
spectroscopy; PaCO2, partial pressure of carbon dioxide; PEEP, positive end-
expiratory pressure; Pi, perfusion index; PI, pulsatility index; PLR test, passive leg
raising test; Pplat, plateau pressure; rSO2, cerebral oxygenation; SpO2, peripheral
saturation of oxygen; TCD, transcranial Doppler.
FC and/or NE—when clinically indicated—on static CA [CA
index measured by transcranial Doppler (TCD)]. Secondary
outcomes were to evaluate the effects of PLR test, FC, and NE on
systemic hemodynamic variables, cerebral oxygenation [regional
cerebral oxygen saturation (rSO2)], and non-invasive intracranial
pressure (nICP).
MATERIALS AND METHODS
A single-center, prospective observational study was conducted
at Policlinico San Martino, IRCCS for Oncology and
Neuroscience, Genoa, Italy. This study is reported according
to the Strengthening the Reporting of Observational Studies
in Epidemiology statement guidelines for observational cohort
studies (Supplementary Material 1) (11). The local ethical
review board approved the protocol (Comitato Etico Regione
Liguria, protocol n. CER Liguria: 23/2020). Mechanically
ventilated patients admitted to ICU during the second wave
of COVID-19 pandemic (from the October 1 to December 15,
2020) were included. COVID-19 patients were defined with
a confirmed SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2) polymerase chain reaction using nasopharyngeal
swab or bronchoalveolar lavage. Inclusion criteria were (1) ≥18
years old; (2) mechanically ventilated severe COVID-19 patients
requiring a PLR test as well as FC and/or NE administration,
according to the indications of the attending physician, during
the occurrence of hypotension [defined as MAP ≤65mm Hg
and/or systolic blood pressure (SBP) ≤90mm Hg]; and (3)
patients undergoing multimodal neuromonitoring [including
cerebral oxygenation using near-infrared spectroscopy (NIRS)
and TCD].
Exclusion criteria were (1) patients with a limited acoustic
window for TCD assessment, which might have led to a non-
precise measurement of the cerebral flow velocities; and (2)
patients with known neurological conditions before or during
ICU admission, which might have impaired CA (stroke, trauma,
intracerebral masses, etc.).
Data Collection
Data were reviewed and collected by physicians trained in critical
care patients’ electronic medical records. Baseline characteristics,
including demographic and clinical data, were collected at ICU
admission. Patients’ data have been partially previously presented
Robba et al. (12). Data collection included age, gender, Sequential
Organ Failure Assessment, body mass index, comorbidities
(hypertension, diabetes mellitus, chronic kidney injury, chronic
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respiratory disease, previous neurological disease, liver failure,
chronic cardiac disease), laboratory parameters [blood test, D-
dimer, C-reactive protein, procalcitonin, creatinine, hemoglobin
(Hb)], and ventilatory parameters [tidal volume (VT), fraction
of inspired oxygen (FIO2), respiratory rate (RR), positive
end-expiratory pressure (PEEP), plateau pressure (Pplat), and
respiratory system compliance].
General Management in ICU
Patients were sedated with a combination of propofol,
midazolam, and fentanyl and mechanically ventilated using
pressure-controlled ventilation, aimed at maintaining Pplat
<28 cmH2O, using a VT of 4–8 mL/kg of predicted body weight.
FIO2 and PEEP were titrated in order to achieve peripheral
saturation of oxygen (SpO2) 88–92%, and RR was set to maintain
arterial partial pressure of carbon dioxide (PaCO2) = 35–45mm
Hg. Permissive hypercapnia was allowed as long as arterial
pH was maintained ≥7.35. Specific ventilatory management
has been previously described in Robba et al. (12). Invasive
arterial blood pressure (ABP), heart rate (HR), and end-tidal
carbon dioxide (ETCO2) were continuously measured. Using a
Masimo root device with pulse CO–oximetry sensors connected
to Rainbow devices, total Hb, perfusion index (Pi), and pleth
variability index were non-invasively measured.
Hemodynamic Management
PLR test was performed to assess fluid responsiveness during
episodes of hypotension. With the patient seated at 45◦ in a
head-up semirecumbent position (T0PLR), patient’s upper body
was then lowered to a horizontal position with legs passively
raised at 45◦, for 30–90 s. At the end of the procedure, before
repositioning patient’s legs, T1PLR was defined (13–15). We
considered a positive PLR test with 5% of ETCO2 increase in
Delta ETCO2 from T0PLR to T1PLR (16, 17), as a surrogate of
10% increase in stroke volume (cardiac output monitor) (13). As
this study is observational and did not change our practice, we
did not have the possibility during the pandemic to use a more
advanced hemodynamic tool in all our patients. Despite ETCO2
is not the criterion standard for PLR test evaluation, it has been
previously used, and it demonstrated to be strongly associated
with stroke volume changes, and therefore, it is now widely
acceptable (13, 14, 17). According to the ETCO2 response to the
PLR test as well as recommendation of the attending physician,
patients received FC [crystalloids (4 mL/kg over 20min)] (14, 15,
18) or NE infusion (central venous at a controlled rate using an
infusion pump with an initial dose of 0.05 µg/kg per minute).
NE infusion was then eventually started in PLR non-responding
patients, or after FC, according to recommendation of attending
physician if another episode of hypotension occurred. T0FC and
T0NE were evaluated at the beginning of FC and NE infusion,
whereas T1FC and T1NE were considered at the end of FC
administration or at timepoints of 5min after the beginning of
NE, when the NE dosage was titrated (starting with a dose of
0.05 µg/kg per minute) to maintain an MAP >65mm Hg. A
complete hemodynamic assessment (HR, ABP, MAP, Hb, SpO2,
Pi, and PVI) and neuromonitoring evaluation (TCD- and NIRS-
derived indices) were obtained at timepoints T0 and T1 of FC and
NE administration. No other interventions (such as mechanical
ventilation settings changes, repositioning of the patient) were
performed between T0 and T1.
Neuromonitoring Data
During the second wave of the pandemic, we started to use
neuromonitoring tools in all our patients as routine, at least in the
early phases from ICU admission, as we noticed a high number
of neurological complications (5).
Cerebral Oxygenation
Masimo Root monitor R© (USA) was used for the continuous
measurement of rSO2 through bilateral sensors applied to the
frontotemporal area. Different indices derived were obtained
including (1) rSO2, which represents the total regional cerebral
oxygen saturation value; (2) variation of O2Hbi, 1O2Hbi,
which represents the modifications of the oxygenated (arterial)
component of the Hb of the total rSO2, whereas 1HHbi defines
the variation of the deoxygenated (venous) component of Hb
of the total value of rSO2; (3) 1cHbi, which is the sum of
the values of 1O2Hbi and 1HHbi; and (4) 1SpO2-rSO2 which
represents the differences between the value of systemic and
cerebral oxygenation. Final values were calculated as the mean
between the right and left frontotemporal sensors.
Calculation of Static CA
CA index was measured using TCD. Percentage change in
estimated cerebrovascular resistance (CVRe) in relation to the
change in ABP over the entire period of time needed for an
MAP increase from baseline (T0) to the higher level (T1) was
calculated as CVRe = MAP/(cerebral blood flow velocity) (19).
We calculated CA index as CA= (% 1CVRe/% 1MAP)× 100%
as previously described (19). We expressed the CA index as a
percentage of full autoregulatory capacity. A change in CVR,
which would fully compensate for the drop in MAP, would yield
a static CA of 100%, whereas no response of CVR, after ABP
changes, would yield a static CA of 0%.
nICP Assessment
Transcranial color duplex Doppler technique (Philips, Bothell,
WA, USA) was performed with a low-frequency (2 MHz)
echographic micro convex through a temporal window to assess
bilateral middle cerebral arteries (MCAs). Systolic, diastolic, and
mean flow velocity (FVs, FVd, and FVm, respectively) were
obtained bilaterally from the MCA.
nICP was measured using two different formulas:
(1) FVd formula (nICPFVd) (20, 21):
nCPP = MAP∗(FVd/FVm)+ 14,
where nCPP is non-invasive cerebral perfusion pressure and then
nICP = MAP− nCPP,
(2) Pulsatility index (PI)–based nICP (nICPPI):
PI was measured according to the Gosling formula (22):
PI = (FVs− FVd)/Fm,
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Estimation based on TCD-derived PI was based on the linear
regression among known values of ICP and PI previously
analyzed by Budohoski et al. (23):
nICPPI = 4.47∗PI+ 12.68
The final nICPPI was calculated using the mean of the right and
left PI, whereas nICPFVd was calculated using the mean flow
velocity of both MCAs.
Statistical Analysis
No data on cerebral oxygenation after PLR test, FC, and NE
are available in COVID-19 patients. Therefore, a formal sample
size calculation was not feasible a priori. However, the achieved
sample size was comparable to other physiologic studies in the
field (24). The Shapiro–Wilk test was used to test the normality
of the distribution of the results. Data are reported as median
and interquartile range (IQR = 25th−75th percentiles), if not
otherwise specified. Comparisons between different variables
at T0 and T1 were performed by paired t-test, whereas non-
normally distributed variables were compared by Wilcoxon
signed rank test. One-way repeated-measures analysis of variance
and Friedman test, followed by Bonferroni post-hoc test, were
used for parametric and non-parametric data, respectively.
Correlations between cerebral and systemic oxygenation were
evaluated using Pearson or Spearman test. Correlations with
repeated measurements were computed according to the Bland
and Altman method (25). All statistical analyses were performed
using SPSS 21 R© (IBM Corp., USA). p < 0.05 was considered
statistically significant.
RESULTS
Baseline characteristics of the patients are presented in Table 1.
The median age of the population was 62 years (IQR = 57–
68.5 years), and 78% of the patients were male. Table 2 presents
the hemodynamic and neuromonitoring parameters analyzed
in the different subgroups [PLR (n = 23), FC (n = 22), and
NE (n = 14)]. In all cases, PLR test was positive, and in
22 cases, FC was used as first-line treatment. In one patient,
who presented with important fluid overload and respiratory
failure, NE was started even with a positive PLR, based on
the recommendation of ICU physician and patient’s clinical
conditions. After FC administration, despite a good initial
response of MAP, 14 patients also required NE following another
episode of hypotension (range between 0.05 and 1.5 µg/kg
per minute).
Effect of PLR Test, FC, and NE on CA
PLR test resulted in a CA index of 58% (44–76.3%), whereas FC
and NE of 90.8% (74.2–100%) and 98% (96–100%), respectively.
CA index did not differ between FC and NE (p = 0.169)
(Figure 1). nICPPI (p = 0.542), nICPFVd (p = 0.529), and
nCPP (p = 0.722) did not differ significantly between FC and
NE (Supplementary Figures 1–3). NE yielded higher values of
rSO2 compared to FC (Supplementary Figure 4) (NE vs. FC;
p= 0.043).
TABLE 1 | Characteristics of the patients included in the study.
Characteristics of patients All patients (n = 23)
Demographics
Gender, male, n (%)
Age (years), median (IQR)
BMI (kg/m2), median (IQR)






Respiratory disease, n (%)
Cardiovascular disease, n (%)
Cancer, n (%)
Moderate/severe liver disease, n (%)
End-stage kidney injury, n (%)
Hypertension, n (%)








ICU characteristics at admission
SOFA score, median (IQR)
Pao2/Fio2, median (IQR)
PEEP, median (IQR)
VT (mL), median (IQR)
Pplat,rs (cm H2O), median (IQR)
Crs (mL/cm H2O), median (IQR)
D-Dimer (ng/mL), median (IQR)
C-reactive protein (mg/dL), median (IQR)
Procalcitonin (ng/mL), median (IQR)
Interleukin 6 (pg/dL), median (IQR)
Creatinine (mg/dL), median (IQR)
Heart rate (bpm), median (IQR)



















IQR, interquartile range; n, number; BMI, body mass index; PBW, predicted body
weight; SOFA, Sequential Organ Failure Assessment; ICU, intensive care unit; Pao2/F io2,
arterial oxygen partial pressure/fraction of inspired oxygen; PEEP, positive end expiratory
pressure; VT , tidal volume; Pplat,rs, respiratory system plateau pressure; Crs, respiratory
system compliance.




After PLR test, MAP was increased [63 (59–64.5) vs. 69
(67.5–71.5) mm Hg, p < 0.001] and rSO2 [52% (51–59.5%) vs.
57% (54–63.5%), p < 0.001], as well as nICPPI and nICPFVd
[18.6 (17.7–19.6) vs. 19.3 (18.2–19.8) mm Hg, p = 0.009, and
12.9 (8.5–18) vs. 15 (10.5–19.7) mm Hg, p = 0.001, respectively
(Table 2)].
Fluid Challenge
Fluid administration resulted in a significant increase inMAP [61
(59–65) vs. 69 (67–72) mm Hg, p < 0.001], rSO2 [55 (52–60) vs.
58 (56–65)%, p < 0.001], and nICPFVd [10.9 (6.7–15.7) vs. 14.4
(5.6- 21.1) mm Hg, p = 0.004] but not nICPPI [19.6 (14.8–21.1)
vs. 18.2 (16.4–19.1) mm Hg, p= 0.153] (Table 2).
Frontiers in Neurology | www.frontiersin.org 4 June 2021 | Volume 12 | Article 674466
Robba et al. Brain-Heart Cross Talk
TABLE 2 | Hemodynamic and neuromonitoring variables before (T0) and after (T1) passive leg raising test, fluid challenge, and norepinephrine.
Passive leg raising test (n = 23) Fluid challenge (n = 22) Norepinephrine (n = 14)
Parameter T0 T1 p-Value T0 T1 p-Value T0 T1 p-Value
Hemodynamics
MAP (mm Hg) 63 (59–64.5) 69 (67.5–71.5) <0.001* 61 (59–65) 69 (67–72) <0.001* 63.5 (61–64) 69 (66–71) <0.001*
HR (bpm) 76 (66.5–88.5) 77 (67–86) 0.822 75.5 (67–89) 75 (67–92) 0.910 76.5 (65–87) 78.5 (67–87) 0.239
Hb (g/dL) 7.9 (7.6–8.4) 8.2 (7.9–8.4) 0.132 7.7 (7.1–8.6) 8.5 (8.1–8.8) 0.434 8.3 (7.8–8.4) 8.8 (8.2–9) 0.432
PVI 20 (16–24) 15.5 (12–19) <0.001* 20 (16–24) 16 (12–19) <0.001* 19 (16–23) 19 (15–23) 0.324
Pi 3 (3–4) 4 (4–5) <0.001* 3 (3–4) 4 (4–5) <0.001* 3 (3–4) 4 (3–4) 0.046*
Neuromonitoring
rSo2 (%) 52 (51–59.5) 57 (54–63.5) <0.001* 55 (52–60) 58 (56–65) <0.001* 54.5 (53–62) 61.5 (61–66) 0.001*
1cHbi 4.7 (3.6–6.6) 6 (5–8) <0.001* 5.3 (3.1–7) 6.6 (4.5–8.4) <0.001* 5.3 (4.3–8.1) 7.3 (5.4–10.5) 0.001*
1O2Hbi 3.8 (2.8–4.5) 4.1 (3.2–5) <0.001* 3.5 (2.8–4.6) 3.9 (3.2–5.6) <0.001* 3.9 (3.2–4.3) 5.7 (3.9–7.1) 0.001*
1HHbi 1.1 (0.8–1.9) 2.1 (1.8–2.9) <0.001* 1.2 (0.4–2.1) 2.4 (1.4–3.1) <0.001* 1.8 (0.7–2.9) 1.9 (0.9–3) 0.143
nICPPI (mm Hg) 18.6 (17.7–19.6) 19.3 (18.2–19.8) 0.009* 19.6 (14.8–21.1) 18.2 (16.4–19.1) 0.153 17.6 (16.5–20.3) 17.5 (16.5–19.9) 0.216
nICPFVd (mm Hg) 12.9 (8.5–18) 15 (10.5–19.7) 0.001* 10.9 (6.7–15.7) 14.4 (5.6 (21.1) 0.004* 10 (6.9–21.3) 12.2 (5.5–22.6) 0.022*
nCPP (mm Hg) 49.9 (42.1–53.8) 54.5 (49.3–59.6) <0.001* 49.6 (44.8–61.1) 54.9 (50.7–65) <0.001* 53.5 (41.2–60.5) 57.4 (45.3–62.5) <0.001*
CVR (mm Hg/cm per second) 1.1 (1–1.2) 1.2 (1.1–1.4) <0.001* 1.1 (1–1.2) 1.2 (1.1–1.3) <0.001* 1.2 (1.1–1.2) 1.2 (1.2–1.3) 0.001*
Others
ETCO2 (mm Hg) 43 (40–47) 46 (43–52.5) 0.001* 43 (38–51) 46.5 (44–50) 0.047* 43.5 (38–47) 45 (41–55) 0.001*
Spo2 (%) 90 (88–92) 91 (88–92) 0.854 90 (89–92) 91 (89–92) 0.357 89.5 (87–94) 89.5 (87–94) 0.317
DeltaSpo2-rSo2 (%) 36 (32–38.5) 32 (28–35.5) <0.001* 35 (30–37) 32 (27–35) <0.001* 33 (29–37) 26 (25–32) 0.001*
Values are expressed as median and interquartile range if not otherwise specified. Hemodynamic and neuromonitoring variables before (T0) and after (T1) passive leg raising test, fluid
challenge, and norepinephrine. Values are expressed as median and interquartile range if not otherwise specified. rSo2, cerebral oxygenation saturation; Delta O2Hbi (1O2Hbi), variation
of the oxygenated component of the hemoglobin (Hb); Delta HHbi (1HHbi), variations of the deoxygenated component of Hb; Delta cHbi (1cHbi), sum of the values of 1O2Hbi and
1HHbi in the calculation of rSo2 value (1cHbi = 1HHbi + 1O2Hbi); 1Spo2-rSo2, difference between the value of Spo2 and rSo2; N, number; MAP, mean arterial pressure; HR, heart
rate; Pi, perfusion index; PVI, pleth variability index; ETCO2, end-tidal carbon dioxide; nCPP, non-invasive cerebral perfusion pressure; nICPPI, non-invasive intracranial pressure (ICP)
based on pulsatility index; nICPFVd, non-invasive ICP based on flow velocity diastolic (FVd) formula; CVR, cerebrovascular resistance. *p < 0.05.
Norepinephrine
The administration of NE led to a significant increase in MAP
[63.5 (61–64) vs. 69 (66–71) mm Hg, p < 0.001] and of rSO2
[54.5% (53–62%) vs. 61.5% (61–66%), p = 0.001] (Table 2), but
only the arterial component improved [1O2Hbi = 3.9 (3.2–4.3)
vs. 5.7 (3.9–7.1), p= 0.001]. nICPFVd slightly increased [10 (6.9–
21.3) vs. 12.2 (5.5–22.6) mmHg, p= 0.022], but not nICPPI [17.6
(16.5–20.3) vs. 17.5 (16.5–19.9) mm Hg, p= 0.216].
DISCUSSION
In the present study, we investigated the effects of PLR test,
FC, and NE on cerebral physiology in mechanically ventilated
patients with severe COVID-19 pneumonia. We found that (1)
PLR test is associated with impaired CA; (2) FC and NE yield
increased MAP, CPP, and rSO2. However, rSO2 is significantly
higher after NE therapy compared to FC.
This is the first study exploring the effects of hemodynamic
changes on cerebral hemodynamics in critically ill COVID-
19 patients undergoing mechanical ventilation. This topic
is of clinical importance, but not sufficiently highlighted
in the literature. Patients with COVID-19 are at high risk
of hemodynamic instability, because of sedation, mechanical
ventilation, and eventually sepsis with direct negative effect
FIGURE 1 | Percentage of cerebral autoregulation index. Data are expressed
as mean, standard deviation. PLRT, passive leg raising test; FC, fluid
challenge; NE, norepinephrine.
on cardiac function, yielding cardiological complications (26–
28). Maintenance of hemodynamic stability and the prompt
treatment of hypotensive events are fundamental in this cohort of
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patients, to provide systemic organ perfusion and an appropriate
CPP to the brain (29). In fact, COVID-19 patients are at
risk of short- and long-term neurological complications (5,
8). The occurrence of stroke is increased in this population
(30), and it appears to be greater in patients with COVID-
19 when compared to those with influenza (1.6 vs. 0.2%,
respectively, with odds ratio 7.6) (31). This higher incidence
has been attributed to the increased incidence of both venous
and arterial thromboembolism. In this context, it is well-known
that hemodynamic instability and in particular hypotension and
altered autoregulation are important risk factors for cerebral
damage and secondary brain injury (6, 29, 32, 33). Although
COVID-19 patients are not primarily brain-injured patients,
recent evidence suggests that the cerebrovascular dynamics are
impaired in this cohort of patients, with altered intracranial
pressure and pupillometer indexes in most cases (8, 10, 34).
Moreover, impaired CA is associated with poor outcome not
only in brain-injured patients, but also in several other groups
of patients, such as sepsis and cardiac arrest (6, 34, 35). PLR
test is often used in the clinical practice as a test to assess the
need for fluids and to help in the decision of starting fluid
therapy or vasopressors; however, PLR test causes an intrinsic
increase in intravascular volume, with shift of intravascular
fluids from the legs to the abdominal compartment. This
may increase intra-abdominal and intrathoracic pressures (36),
yielding impaired cerebral hemodynamics and for this reason
has been often discouraged in patients at risk of intracranial
complications (37). There are few previous studies including
a minority of ICU patients with brain injury who underwent
PLR test [i.e., two of 34 patients in the study by Biais et al.
(38), six of 71 patients in the study by Monnet et al. (39)],
and no specific data on this subpopulation are available. The
best hemodynamic strategy to optimize cerebral perfusion and
autoregulation remains unclear. Fluid therapy is often used as
first-line therapy in critically ill patients with hypotension (36),
inducing a transient increase in cardiac preload consequent to
extrinsic increase in intravascular volume, whereas vasopressors
are started to improve MAP acting on vasomotor tone. The
choice to use PLR test in these patients and treat them with
fluids or vasopressors should depend on both lung and cerebral
needs, which are often in conflict (40, 41). Our results suggest that
PLR test may significantly decrease the cerebral autoregulatory
system function of COVID-19 patients. PLR test can also increase
ICP, suggesting that it may not be appropriate in patients at
risk of cerebral complications. FC and NE were able to increase
MAP and CPP, but NE seems to have a better effect on cerebral
oxygenation and autoregulation, even though no differences
in MAP and CPP between the three strategies were observed
at T1.
The impact of vasopressors and FC on CA is not completely
understood. Klein et al. (42) recently found in a cohort of
91 traumatic brain injury and 13 stroke patients that dynamic
intracranial pressure–based measurements of cerebrovascular
reactivity are not affected by NE. Similarly, Johnston et al.
(43) suggested that CPP augmentation with NE, but not with
dopamine, resulted in a significant reduction in arterial–venous
oxygen difference (37 ± 11 vs. 33 ± 12 mL/L) and a significant
increase in brain tissue oxygen (2.6± 1.1 vs. 3.0± 1.1 kPa).
The mechanism according to which NE—compared to
fluids—could potentially better preserve autoregulation and
cerebral oxygenation might be related to a greater effect of NE
on the arterial component of rSO2, 1O2Hbi, compared to FC.
Furthermore, this could be related to specific characteristics
of NE and the brain-blood barrier (BBB), which contains
monoaminoxidase, thus allowing preserving cerebral vessels
from its potential vasoconstrictor effects. Indeed, previous
evidence confirms that NE has neuroprotective effects and
improves CA (44) and oxygenation (43), leading to a significant
increase in cerebral blood flow, in both conditions when BBB
is intact or experimentally opened (45). No data are available
regarding the effect of FC on CA so far, but potentially changes
in plasma osmolarity and vascular content might have less
protective effect on cerebral hemodynamics and BBB.
Limitations
This study presents several limitations. First, the sample
size of the patients included is small, especially considering
each subgroup; however, no data are available in COVID-19
patients on this topic. Moreover, the number of patients in
the current study is higher than that in similar studies on
brain-injured patients (46). Second, the response to PLR test
was defined according to changes of ETCO2, which is not
the criterion standard (36, 47); the ETCO2 has been already
used in patients with acute respiratory distress syndrome and
NE infusion showing a better performance, as compared to
systemic pressure (48). To the best of our knowledge, no
data are available so far in COVID-19 patients regarding this
use; however, we considered the performance of this surrogate
good enough in a context of paucity of resources. Third,
our results would have been strengthened by the availability
of more specific data on physiological parameters including
invasive neurologic, respiratory, and hemodynamic monitoring
to assess the changes consequent to the application of the
different hemodynamic strategies. In particular, the use of
invasive ICP and oxygenation would have been of extreme
utility, but no indications are available for their use in non-
primarily brain-injured patients. Also, our population represents
a specific subgroup with peculiar characteristics, and therefore,
our results may not be applicable in other clinical settings.
Fourth, PLR is a test, whereas FC and NE administration
are two types of clinical interventions, and therefore, these
are not comparable. The decision whether to avoid PLR test
in patients at risk of cerebral complications should take into
account patients’ needs and clinical conditions, and further
larger studies are warranted to clarify this issue. In addition,
as some patients received both FC and NE, we cannot
exclude a cumulative effect of these techniques. Finally, we
evaluated the early effects of PLR test on static CA, and no
information is provided from our results on a long-term effect
of this technique.
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CONCLUSIONS
In mechanically ventilated severe COVID-19 patients, PLR test
results in a reduction of cerebral autoregulatory function. PLR
test, FC, and NE increased cerebral oxygenation, but NE seemed
to have the major beneficial effect on cerebral oxygenation
compared to FC. An individualized strategy aimed at assessing
both the hemodynamic and cerebral needs is warranted in
COVID-19 patients at high risk of neurological complications.
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